Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Editas Medicine Inc(EDIT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EDIT
09/28/2026: EDIT (1-star) is currently NOT-A-BUY. Pass it for now.
Editas Medicine is a clinical-stage biotechnology firm dedicated to developing CRISPR-based therapies for genetic diseases, including sickle cell and blood disorders. The company’s primary strength lies in its strong intellectual property portfolio and a focused, though early-stage, clinical pipeline. Its main growth opportunity centers on the potential regulatory approval of its lead gene-editing candidate, reni-cel. However, the company faces significant risks, including intense competition from more established players, consistent operating losses, and the inherent uncertainty of clinical development. It is best suited for growth-oriented investors who can tolerate high volatility while monitoring developments in clinical efficacy and potential strategic partnerships.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to the gene-editing sector, but growth is speculative until commercial milestones are met. |
| Momentum investor | Mixed fit | The stock can experience sharp moves based on clinical data releases, making it conditional on positive news flow. |
| Value investor | Weak fit | As a pre-profit clinical-stage biotech, the company lacks the earnings or cash flow metrics typically sought by value investors. |
| Dividend investor | Weak fit | Editas is a capital-intensive R&D firm and does not pay dividends. |
| Low-risk investor | Weak fit | High volatility and the inherent uncertainty of drug development make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks fluctuate wildly based on trial results and news. |
| Valuation risk | High | Without recurring revenue, valuation is highly sensitive to optimistic future growth assumptions. |
| Competition risk (Gene-editing) | High | Well-capitalized competitors like VRTX have already established early leads in key markets. |
| Business quality | Medium | While the technology is innovative, the company is still unproven in bringing a drug to commercial market. |
| Dividend income | Low / none | Investors should expect zero income as capital is burned for development. |
| Execution risk | High | Failure to achieve positive clinical endpoints would represent a major setback to the company's viability. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 5.61% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 396.24M USD | Price to earnings Ratio - | 1Y Target Price 5.9 |
Price to earnings Ratio - | 1Y Target Price 5.9 | ||
Volume (30-day avg) 3.3M shares | Beta 2.09 | 52 Weeks Range 1.66 - 4.54 | Updated Date 09/27/2026 |
52 Weeks Range 1.66 - 4.54 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.66 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Upfront payments, milestone payments, and potential future royalties from strategic partnerships. | Revenue is sporadic and tied to the success of partnerships rather than consistent product sales. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 213.92M | Price to Sales(TTM) 8.43 |
Enterprise Value 213.92M | Price to Sales(TTM) 8.43 | ||
Enterprise Value to Revenue 4.55 | Enterprise Value to EBITDA -1.36 | Shares Outstanding 153.58M | Shares Floating 115.49M |
Shares Outstanding 153.58M | Shares Floating 115.49M | ||
Percent Insiders 0.18 | Percent Institutions 79.29 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Editas Medicine Inc
Exchange NASDAQ | Headquarters Cambridge, MA, United States | ||
IPO Launch date 2016-02-03 | President, CEO & Director Dr. Gilmore O'Neill M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 87 | Website https://www.editasmedicine.com |
Full time employees 87 | Website https://www.editasmedicine.com | ||
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.